FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company's PanTracer portfolio.
NeoGenomics, Inc. (NASDAQ:NEO ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Anthony P. Zook - CEO & Director Jeffrey S.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, with the option to add HRD testing.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will debut its PanTracer Family and unveil the Paletrra platform at ASCO 2025, advancing precision oncology diagnostics.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.